Comparative Pharmacology
Head-to-head clinical analysis: EMERPHED versus EPI E Z PEN JR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMERPHED versus EPI E Z PEN JR.
EMERPHED vs EPI E Z PEN JR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EMERPHED is a combination of ephedrine and phenylephrine. Ephedrine is a sympathomimetic amine that acts directly on alpha and beta adrenergic receptors and indirectly by releasing norepinephrine from nerve endings, causing vasoconstriction, bronchodilation, and increased heart rate and blood pressure. Phenylephrine is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction and increased blood pressure.
Epinephrine is a direct-acting sympathomimetic amine that acts on alpha- and beta-adrenergic receptors. Alpha receptor activation increases peripheral vascular resistance and reverses hypotension, while beta receptor activation causes bronchodilation, increased heart rate, and myocardial contractility.
Adults: 1-2 capsules (25-50 mg ephedrine sulfate) orally every 3-4 hours as needed, not to exceed 150 mg in 24 hours.
Epinephrine 0.3 mg (0.3 mL of 1:1000 solution) intramuscularly into the anterolateral thigh, repeated every 5-15 minutes as necessary for anaphylaxis.
None Documented
None Documented
Terminal elimination half-life: 3-6 hours (prolonged in renal impairment: up to 15 hours).
Short terminal half-life of approximately 2-3 minutes; requires continuous infusion for sustained effect due to rapid uptake and metabolism.
Renal excretion of unchanged drug (~30-50%) and metabolites; minor biliary/fecal elimination (<10%).
Primarily renal: epinephrine is metabolized in the liver and tissues, with metabolites (metanephrine, vanillylmandelic acid) excreted in urine; <5% excreted unchanged.
Category C
Category C
Sympathomimetic
Sympathomimetic